Thymosin Alpha-1 Study Index
Thymosin Alpha-1 (Ta1) is a 28-amino acid peptide naturally produced by thymic epithelial cells and first isolated by Allan Goldstein and colleagues in 1977. Its primary mechanism involves activation of Toll-like receptors (TLR2 and TLR9) on dendritic cells and macrophages, promoting innate immune signaling, antigen-presenting cell maturation, and T-cell differentiation. Downstream effects include enhanced cytotoxic T-cell activity, modulation of regulatory T-cells, and cytokine balance adjustments relevant to antiviral defense and anti-tumor immunity. Thymosin Alpha-1 has been evaluated in human clinical trials for hepatitis B, hepatitis C, cancer immunotherapy, and sepsis-related immune dysfunction.
Studies Listed
6
Curated Study References
Click column headers to sort. PubMed links open in a new tab where available.
| Authors ↕ | Year ↓ | Journal ↕ | Key Finding | PubMed |
|---|---|---|---|---|
| Romani et al. | 2012 | European Journal of Immunology | Thymosin Alpha-1 modulated dendritic cell function through tryptophan catabolism, promoting regulatory immune balance and tolerance mechanisms alongside pro-inflammatory immune activation depending on context. | 22585631 ↗ |
| Wu et al. | 2012 | Cellular and Molecular Immunology | Thymosin Alpha-1 enhanced NK cell function and cytotoxicity against HIV-1 infected cells, extending its immune modulation research profile to viral immune defense contexts beyond hepatitis. | 21985301 ↗ |
| Liu et al. | 2004 | World Journal of Gastroenterology | Meta-analysis of clinical trials demonstrating that Thymosin Alpha-1 treatment significantly improved HBe antigen seroconversion and viral suppression rates compared to controls in chronic hepatitis B patients, providing clinical evidence for its immune activation in chronic viral infection. | 15285029 ↗ |
| Garaci et al. | 2000 | European Journal of Cancer | Thymosin Alpha-1 combined with chemotherapy in non-small cell lung cancer patients improved immune parameters and survival outcomes compared to chemotherapy alone, demonstrating its potential as an immunotherapy adjunct in oncology models. | 10619647 ↗ |
| Matteucci et al. | 2000 | International Journal of Immunopharmacology | Thymosin Alpha-1 activated NF-kB-dependent NK cell cytotoxicity in immune cells from chronic hepatitis patients, providing mechanistic detail for how its TLR signaling translates to improved anti-viral immune function. | 11090697 ↗ |
| Goldstein et al. | 1977 | Proceedings of the National Academy of Sciences | First isolation and complete sequence characterization of Thymosin Alpha-1 from calf thymus tissue, establishing it as the active immunomodulatory component of the thymosin fraction with potent T-cell stimulatory properties. | 265583 ↗ |
Romani et al.
2012, European Journal of Immunology
Thymosin Alpha-1 modulated dendritic cell function through tryptophan catabolism, promoting regulatory immune balance and tolerance mechanisms alongside pro-inflammatory immune activation depending on context.
Wu et al.
2012, Cellular and Molecular Immunology
Thymosin Alpha-1 enhanced NK cell function and cytotoxicity against HIV-1 infected cells, extending its immune modulation research profile to viral immune defense contexts beyond hepatitis.
Liu et al.
2004, World Journal of Gastroenterology
Meta-analysis of clinical trials demonstrating that Thymosin Alpha-1 treatment significantly improved HBe antigen seroconversion and viral suppression rates compared to controls in chronic hepatitis B patients, providing clinical evidence for its immune activation in chronic viral infection.
Garaci et al.
2000, European Journal of Cancer
Thymosin Alpha-1 combined with chemotherapy in non-small cell lung cancer patients improved immune parameters and survival outcomes compared to chemotherapy alone, demonstrating its potential as an immunotherapy adjunct in oncology models.
Matteucci et al.
2000, International Journal of Immunopharmacology
Thymosin Alpha-1 activated NF-kB-dependent NK cell cytotoxicity in immune cells from chronic hepatitis patients, providing mechanistic detail for how its TLR signaling translates to improved anti-viral immune function.
Goldstein et al.
1977, Proceedings of the National Academy of Sciences
First isolation and complete sequence characterization of Thymosin Alpha-1 from calf thymus tissue, establishing it as the active immunomodulatory component of the thymosin fraction with potent T-cell stimulatory properties.
All citations are for informational research reference purposes. Always verify directly via PubMed for current status.
Research Questions
Common questions about Thymosin Alpha-1 research context, mechanism, and procurement.
What is Thymosin Alpha-1 and what is its primary immune mechanism?+
What hepatitis B clinical research exists for Thymosin Alpha-1?+
Has Thymosin Alpha-1 been studied as a cancer immunotherapy adjunct?+
What does Thymosin Alpha-1 research show about regulatory immune balance?+
Related Compound Comparisons
Explore how Thymosin Alpha-1 compares to other research compounds.
Source Thymosin Alpha-1
Thymosin Alpha-1 is available from Spartan Peptides at least 98% HPLC-verified purity. Domestic US supply with same-day dispatch before 2 PM. For in-vitro research use only.
Order Thymosin Alpha-1 ($99)For in-vitro research use only. Not intended for human consumption.